|
YIPF5 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 2.2055000048482E-08 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
7.64180000389914E-08 |
| Normal-vs-Stage2 |
1.201310E-04 |
| Normal-vs-Stage3 |
1.63470000003052E-06 |
| Normal-vs-Stage4 |
9.52599999992643E-07 |
| Stage1-vs-Stage2 |
9.693400E-01 |
| Stage1-vs-Stage3 |
6.931000E-01 |
| Stage1-vs-Stage4 |
2.033000E-01 |
| Stage2-vs-Stage3 |
8.296800E-01 |
| Stage2-vs-Stage4 |
3.802600E-01 |
| Stage3-vs-Stage4 |
4.180000E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
4.00330000260851E-08 |
| Normal-vs-AfricanAmerican |
9.048600E-04 |
| Normal-vs-Asian |
1.198870E-04 |
| Caucasian-vs-AfricanAmerican |
7.708200E-01 |
| Caucasian-vs-Asian |
7.494800E-01 |
| AfricanAmerican-vs-Asian |
9.645800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
4.89589999652651E-08 |
| Normal-vs-Female |
1.23179999977907E-07 |
| Male-vs-Female |
2.722200E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.9789999999853E-06 |
| Normal-vs-Age(41-60Yrs) |
1.75240000288568E-08 |
| Normal-vs-Age(61-80Yrs) |
1.91270000005073E-06 |
| Normal-vs-Age(81-100Yrs) |
8.008100E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
3.054800E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
4.957000E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
6.280600E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
8.838200E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
4.009400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
4.809000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
5.116400E-01 |
| Classical-VS-Follicular |
5.237500E-03 |
| Classical-VS-Other |
5.282300E-02 |
| Classical-VS-Normal |
1.8435999999955E-06 |
| Tall-VS-Follicular |
3.375400E-01 |
| Tall-VS-Other |
1.890820E-01 |
| Tall-VS-Normal |
6.575400E-04 |
| Follicular-VS-Other |
3.924800E-01 |
| Follicular-VS-Normal |
5.32049999613093E-08 |
| Other-VS-Normal |
5.396400E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
3.60840000102058E-08 |
| Normal-vs-N1 |
1.13680000002336E-06 |
| N0-vs-N1 |
3.454600E-01 |
|
|
